- Home
- SND vs HLVX Comparison
SND vs HLVX Comparison
Compare SND & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SND
- HLVX
- Stock Information
- Founded
- SND 2011
- HLVX 2020
- Country
- SND United States
- HLVX United States
- Employees
- SND N/A
- HLVX N/A
- Industry
- SND Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- SND Industrials
- HLVX Health Care
- Exchange
- SND Nasdaq
- HLVX Nasdaq
- Market Cap
- SND 92.1M
- HLVX 105.2M
- IPO Year
- SND 2016
- HLVX 2022
- Fundamental
- Price
- SND $1.92
- HLVX $2.05
- Analyst Decision
- SND
- HLVX Hold
- Analyst Count
- SND 0
- HLVX 1
- Target Price
- SND N/A
- HLVX $2.00
- AVG Volume (30 Days)
- SND 77.2K
- HLVX 504.5K
- Earning Date
- SND 08-12-2025
- HLVX 08-11-2025
- Dividend Yield
- SND 5.18%
- HLVX N/A
- EPS Growth
- SND N/A
- HLVX N/A
- EPS
- SND N/A
- HLVX N/A
- Revenue
- SND $293,878,000.00
- HLVX N/A
- Revenue This Year
- SND N/A
- HLVX N/A
- Revenue Next Year
- SND N/A
- HLVX N/A
- P/E Ratio
- SND N/A
- HLVX N/A
- Revenue Growth
- SND N/A
- HLVX N/A
- 52 Week Low
- SND $1.73
- HLVX $1.34
- 52 Week High
- SND $2.80
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- SND 43.06
- HLVX 48.11
- Support Level
- SND $1.76
- HLVX $2.07
- Resistance Level
- SND $2.09
- HLVX $2.16
- Average True Range (ATR)
- SND 0.09
- HLVX 0.07
- MACD
- SND -0.00
- HLVX -0.01
- Stochastic Oscillator
- SND 47.06
- HLVX 29.41
About SND Smart Sand Inc.
Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.